Information Library

Results for: Oncology - Phase II/III

To learn more about Quintiles’ services, you may broaden or narrow your search by selecting the topics at left.

Start Over

  • Sort by:
  • Recently Added
  • Title

  • Quintiles Forms New Biomarker Research and Development Company

    Press Release — January 18, 2012 – Quintiles announced that it has invested in a new company formed to provide oncology consulting services and new cancer biomarkers, the key to scientific selection of the right drug for the right patient.

  • ASCO 2012

    Event — Conference Date(s): June 1 - June 5, 2012
    Location: Chicago, IL McCormick Place
    Booth Number: 2062

  • Energizing Enrollment

    Case Study — October 4, 2011
    The rapid recruitment for this Phase III, open, randomized, controlled, multi-center study in adjuvant triple-negative breast cancer (TNBC) was completed two months earlier than planned.

  • The Molecular Biomarker Revolution in Non-Small Cell Lung Cancer

    White Paper — June 23, 2011
    In this new white paper Quintiles’ experts Christopher Ung, Jason Hill, Carrie Lee and Harish Dave review some of the most promising molecular pathways and targeted approaches for NSCLC, the critical role of diagnostics, and strategies to detect and address the emergence of resistance.

  • Recruiting Trust

    Case Study — March 16, 2011
    Quintiles enrolls 2 cancer trials, 2 times faster than projected

  • Clinical – Smarter Trials, Accelerated Outcomes

    Brochure — February 16, 2011
    Quintiles will work with you to plan and execute the smartest clinical trials and post-marketing studies, informed by a holistic view of strategic, operational, regulatory and marketplace issues.

  • Exclusive Report From Scientific American

    Hear from the Experts — November 9, 2010
    In-depth insights on every angle of the changing health landscape - brought to you by Quintiles Get the report today.

  • Oncology Drug Development and Value-Based Medicine

    White Paper — November 5, 2010
    This report demonstrates the need to converge clinical and commercial imperatives earlier within the drug development process to meet a future demand for value-based medical practices.

  • From Biomarkers to Diagnostics - The Road to Success

    White Paper — October 18, 2010
    In the second installment of a two-part series, Eric Groves, Jason Hill and Christopher Ung walk through the challenges associated with drug-diagnostic co-development, addressing potential pitfalls and areas of opportunity.

  • Management of Tissue Specimens for Oncology Drug Development in China

    Presentation — October 1, 2010
    Download Patty James of Quintiles recent presentation Management of Tissue Specimens for Oncology Drug Development in China from the Clinical Development of Cancer Drugs in China

Page 1 of 3 (29 results)

Subscribe to Email Based on Your Interests

Set preferences